celecoxib has been researched along with Cardiovascular Stroke in 66 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events." | 9.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "We searched for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing aspirin or other NSAIDs with placebo for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 8.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "Etodolac is not associated with a statistically increased risk of acute myocardial infarction compared to naproxen." | 7.74 | The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. ( Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA, 2008) |
| "The results indicate that the volatile anesthetic isoflurane produces a second window of preconditioning against myocardial ischemia and reperfusion injury." | 7.72 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. ( Alcindor, D; Kersten, JR; Krolikowski, JG; Ludwig, LM; Pagel, PS; Pratt, PF; Tanaka, K; Warltier, DC, 2004) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 5.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| "Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID." | 5.24 | Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). ( Connolly, E; Findlay, E; Ford, I; Greenlaw, N; Grobbee, DE; Hallas, J; Hawkey, CJ; Hobbs, FDR; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Perez-Gutthann, S; Ralston, SH; Reid, DM; Ritchie, LD; Ruschitzka, F; Scheiman, JM; Walters, MR; Webster, J; Wei, L; Wilson, A, 2017) |
| "Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events." | 5.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "We searched for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing aspirin or other NSAIDs with placebo for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 4.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| " cerebral infarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users." | 3.76 | Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. ( Einarsdottir, R; Gudbjornsson, B; Halldorsson, M; Johannsson, M; Sigvaldason, H; Thorgeirsson, G; Thorsteinsson, SB; Zoega, H, 2010) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "Etodolac is not associated with a statistically increased risk of acute myocardial infarction compared to naproxen." | 3.74 | The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. ( Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA, 2008) |
| "Although only rofecoxib use was associated with an increased risk of myocardial infarction in those without a previous event, both rofecoxib and celecoxib were associated with an excess risk of acute myocardial infarction for current users with a history of myocardial infarction." | 3.74 | The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. ( Brophy, JM; Lévesque, LE; Zhang, B, 2007) |
| "To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population." | 3.74 | Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. ( Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ, 2007) |
| "Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam." | 3.73 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006) |
| " Using data collected in a previous population-based cohort study of elderly people starting nonsteroidal anti-inflammatory drug (NSAID) therapy, we evaluated the temporal nature of the risk of a first myocardial infarction (MI) associated with the use of rofecoxib and celecoxib." | 3.73 | Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. ( Brophy, JM; Lévesque, LE; Zhang, B, 2006) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| " We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit." | 3.72 | Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. ( Avorn, J; Glynn, RJ; Kiyota, Y; Levin, R; Mogun, H; Schneeweiss, S; Solomon, DH, 2004) |
| "The results indicate that the volatile anesthetic isoflurane produces a second window of preconditioning against myocardial ischemia and reperfusion injury." | 3.72 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. ( Alcindor, D; Kersten, JR; Krolikowski, JG; Ludwig, LM; Pagel, PS; Pratt, PF; Tanaka, K; Warltier, DC, 2004) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "Celecoxib was the first COX-2 inhibitor introduced and the only remaining one on the US market." | 2.43 | Celecoxib and cardiovascular risks. ( Brophy, JM, 2005) |
| " Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ( Davies, NM; Day, RO; McLachlan, AJ; Williams, KM, 2000) |
| "Celecoxib and naproxen were not associated with increased risks." | 1.35 | Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 1.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| "Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2." | 1.31 | Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. ( Bing, RJ; Johnson, PE; Kakar, NR; Vina, ER; Yamamoto, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 56 (84.85) | 29.6817 |
| 2010's | 9 (13.64) | 24.3611 |
| 2020's | 1 (1.52) | 2.80 |
| Authors | Studies |
|---|---|
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Fidahic, M | 1 |
| Jelicic Kadic, A | 1 |
| Radic, M | 1 |
| Puljak, L | 1 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Franklin, JM | 1 |
| Rassen, JA | 1 |
| Ackermann, D | 1 |
| Bartels, DB | 1 |
| Schneeweiss, S | 3 |
| Margulis, K | 1 |
| Neofytou, EA | 1 |
| Beygui, RE | 1 |
| Zare, RN | 1 |
| MacDonald, TM | 1 |
| Hawkey, CJ | 2 |
| Ford, I | 1 |
| McMurray, JJV | 1 |
| Scheiman, JM | 1 |
| Hallas, J | 1 |
| Findlay, E | 1 |
| Grobbee, DE | 1 |
| Hobbs, FDR | 1 |
| Ralston, SH | 1 |
| Reid, DM | 1 |
| Walters, MR | 1 |
| Webster, J | 1 |
| Ruschitzka, F | 1 |
| Ritchie, LD | 1 |
| Perez-Gutthann, S | 1 |
| Connolly, E | 1 |
| Greenlaw, N | 1 |
| Wilson, A | 1 |
| Wei, L | 1 |
| Mackenzie, IS | 1 |
| Lesaffre, E | 1 |
| Feng, GS | 1 |
| Ma, JL | 1 |
| Wong, BC | 1 |
| Zhang, L | 1 |
| Liu, WD | 1 |
| Pan, KF | 1 |
| Shen, L | 1 |
| Zhang, XD | 1 |
| Li, J | 1 |
| Xia, HH | 1 |
| Li, JY | 1 |
| Lam, SK | 1 |
| You, WC | 1 |
| Warner, JJ | 1 |
| Weideman, RA | 1 |
| Kelly, KC | 1 |
| Brilakis, ES | 1 |
| Banerjee, S | 1 |
| Cunningham, F | 1 |
| Harford, WV | 1 |
| Kazi, S | 1 |
| Little, BB | 1 |
| Cryer, B | 1 |
| Lada-Moldovan, L | 1 |
| Kaloustian, S | 1 |
| Bah, TM | 1 |
| Girard, SA | 1 |
| Déry, MA | 1 |
| Rousseau, G | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 1 |
| Chung, CP | 1 |
| Castellsague, J | 1 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Gudbjornsson, B | 1 |
| Thorsteinsson, SB | 1 |
| Sigvaldason, H | 1 |
| Einarsdottir, R | 1 |
| Johannsson, M | 1 |
| Zoega, H | 1 |
| Halldorsson, M | 1 |
| Thorgeirsson, G | 1 |
| Bavry, AA | 1 |
| Khaliq, A | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Cooper-Dehoff, RM | 1 |
| Pepine, CJ | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Aalbers, J | 1 |
| Wooltorton, E | 1 |
| Howes, LG | 1 |
| Krum, H | 1 |
| Kodani, E | 1 |
| Xuan, YT | 2 |
| Shinmura, K | 2 |
| Takano, H | 2 |
| Tang, XL | 3 |
| Bolli, R | 3 |
| Mamdani, M | 1 |
| Rochon, P | 1 |
| Juurlink, DN | 1 |
| Anderson, GM | 1 |
| Kopp, A | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Solomon, DH | 2 |
| Glynn, RJ | 1 |
| Kiyota, Y | 1 |
| Levin, R | 1 |
| Mogun, H | 1 |
| Avorn, J | 1 |
| Tanaka, K | 1 |
| Ludwig, LM | 1 |
| Krolikowski, JG | 2 |
| Alcindor, D | 2 |
| Pratt, PF | 1 |
| Kersten, JR | 2 |
| Pagel, PS | 2 |
| Warltier, DC | 2 |
| Lamarque, D | 1 |
| Misak, A | 1 |
| Couzin, J | 1 |
| Kimmel, SE | 1 |
| Berlin, JA | 1 |
| Reilly, M | 1 |
| Jaskowiak, J | 1 |
| Kishel, L | 1 |
| Chittams, J | 1 |
| Strom, BL | 1 |
| Vanchieri, C | 1 |
| Johnsen, SP | 1 |
| Larsson, H | 1 |
| Tarone, RE | 1 |
| McLaughlin, JK | 1 |
| Nørgård, B | 1 |
| Friis, S | 1 |
| Sørensen, HT | 1 |
| Epstein, RA | 1 |
| Abeles, M | 1 |
| Abeles, AM | 1 |
| Klasser, GD | 1 |
| Epstein, J | 1 |
| Zhao, SP | 1 |
| Deng, P | 1 |
| Huang, HG | 1 |
| Xu, ZM | 1 |
| Dai, HY | 1 |
| Hong, SC | 1 |
| Yang, J | 1 |
| Zhou, HN | 1 |
| Brophy, JM | 3 |
| Huang, WF | 1 |
| Hsiao, FY | 1 |
| Tsai, YW | 1 |
| Wen, YW | 1 |
| Shih, YT | 1 |
| Abbasi, K | 1 |
| Lévesque, LE | 2 |
| Zhang, B | 2 |
| Nelson, NJ | 1 |
| Gislason, GH | 1 |
| Jacobsen, S | 1 |
| Rasmussen, JN | 1 |
| Rasmussen, S | 1 |
| Buch, P | 1 |
| Friberg, J | 1 |
| Schramm, TK | 1 |
| Abildstrom, SZ | 1 |
| Køber, L | 1 |
| Madsen, M | 1 |
| Torp-Pedersen, C | 1 |
| Lee, YH | 1 |
| Ji, JD | 1 |
| Song, GG | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Brookhart, MA | 1 |
| Rahme, E | 2 |
| Watson, DJ | 1 |
| Kong, SX | 1 |
| Toubouti, Y | 1 |
| LeLorier, J | 1 |
| Andersohn, F | 1 |
| Suissa, S | 1 |
| Garbe, E | 1 |
| Chen, JT | 1 |
| Pucino, F | 1 |
| Resman-Targoff, BH | 1 |
| Timmers, L | 1 |
| Sluijter, JP | 1 |
| Verlaan, CW | 1 |
| Steendijk, P | 1 |
| Cramer, MJ | 1 |
| Emons, M | 1 |
| Strijder, C | 1 |
| Gründeman, PF | 1 |
| Sze, SK | 1 |
| Hua, L | 1 |
| Piek, JJ | 1 |
| Borst, C | 1 |
| Pasterkamp, G | 1 |
| de Kleijn, DP | 1 |
| Jugdutt, BI | 1 |
| Nedjar, H | 1 |
| Chen, LC | 1 |
| Ashcroft, DM | 1 |
| Caldwell, B | 1 |
| Beasley, R | 1 |
| Weatherall, M | 1 |
| Metcalfe, S | 1 |
| Madan, RA | 1 |
| Xia, Q | 1 |
| Chang, VT | 1 |
| Oriscello, RG | 1 |
| Kasimis, B | 1 |
| Sato, H | 1 |
| Rokosh, GD | 1 |
| Bi, Q | 1 |
| Dai, S | 1 |
| Shirk, G | 1 |
| Brownstein, JS | 1 |
| Sordo, M | 1 |
| Kohane, IS | 1 |
| Mandl, KD | 1 |
| Brown, JS | 1 |
| Kulldorff, M | 1 |
| Chan, KA | 1 |
| Davis, RL | 1 |
| Graham, D | 1 |
| Pettus, PT | 1 |
| Andrade, SE | 1 |
| Raebel, MA | 1 |
| Herrinton, L | 1 |
| Roblin, D | 1 |
| Boudreau, D | 1 |
| Smith, D | 1 |
| Gurwitz, JH | 1 |
| Gunter, MJ | 1 |
| Platt, R | 1 |
| van Staa, TP | 1 |
| Smeeth, L | 1 |
| Persson, I | 1 |
| Parkinson, J | 1 |
| Leufkens, HG | 1 |
| Cunnington, M | 1 |
| Webb, D | 1 |
| Qizilbash, N | 1 |
| Blum, D | 1 |
| Mander, A | 1 |
| Funk, MJ | 1 |
| Weil, J | 1 |
| Davies, NM | 1 |
| McLachlan, AJ | 1 |
| Day, RO | 1 |
| Williams, KM | 1 |
| Wang, Y | 1 |
| Liu, SQ | 1 |
| Bhatnagar, A | 1 |
| Yamamoto, T | 1 |
| Kakar, NR | 1 |
| Vina, ER | 1 |
| Johnson, PE | 1 |
| Bing, RJ | 1 |
| Zeidler, H | 1 |
| Schnitzer, TJ | 1 |
| Fenn, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's[NCT00447759] | Phase 4 | 7,297 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| VeSpAR: A Randomized Controlled Trial Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Urethral Strictures[NCT03572348] | 100 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | |||
| Differential Efficacy of Guided Imagery Psychotherapy: Comparing Guided Imagery Psychotherapy and Unified Psychodynamic Protocol Therapy for Emotional Disorders in a Non-Inferiority RCT and With Regard to Differential Indication[NCT04765800] | 180 participants (Anticipated) | Interventional | 2021-02-15 | Recruiting | |||
| Rehabilitation for Whiplash Associated Disorders; a Randomized Clinical Trial[NCT05319808] | 180 participants (Anticipated) | Interventional | 2022-05-27 | Active, not recruiting | |||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for celecoxib and Cardiovascular Stroke
| Article | Year |
|---|---|
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Myocardial Infarc | 2017 |
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Suscept | 2002 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
Celecoxib and cardiovascular risks.
Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Respon | 2005 |
Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Decisi | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Re | 2007 |
Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Biotransform | 2000 |
Arthritis. Should you be taking a COX-2 inhibitor?
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo | 2001 |
Cyclooxygenase inhibition: between the devil and the deep blue sea.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2002 |
3 trials available for celecoxib and Cardiovascular Stroke
| Article | Year |
|---|---|
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).
Topics: Acute Coronary Syndrome; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celec | 2017 |
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Topics: Adult; Cardiovascular Diseases; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Dose-Response Relatio | 2008 |
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Topics: Adenoma; Adenomatous Polyps; Angina, Unstable; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactone | 2007 |
53 other studies available for celecoxib and Cardiovascular Stroke
| Article | Year |
|---|---|
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Metrics for covariate balance in cohort studies of causal effects.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Computer Simulation; Data | 2014 |
Celecoxib Nanoparticles for Therapeutic Angiogenesis.
Topics: Angiogenesis Inducing Agents; Animals; Blood Vessels; Celecoxib; Disease Models, Animal; Humans; Isc | 2015 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip | 2008 |
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitor | 2008 |
Chronic pretreatment with celecoxib reduces infarct size.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Infusions, Parenteral; Isch | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
Topics: Angina, Unstable; Celecoxib; Cerebral Infarction; Cyclooxygenase 2 Inhibitors; Databases, Factual; D | 2010 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhi | 2012 |
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi | 2002 |
Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Benzamides; Benzylidene Compounds; Celecoxib; Consciousness; | 2002 |
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhib | 2003 |
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2004 |
Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2.
Topics: Anesthetics, Inhalation; Animals; Blood Pressure; Blotting, Western; Celecoxib; Coronary Circulation | 2004 |
Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anesthetics, Inhalation; Animals; Aspirin; Celecoxib; C | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Coxib medications to be handled with care.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Myocardial Infarction | 2005 |
Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
Topics: Alzheimer Disease; Celecoxib; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; D | 2004 |
Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhib | 2005 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confo | 2005 |
Pfizer: Celebrex increases heart attack risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Myocardial Infarction | 2005 |
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Ce | 2005 |
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celec | 2005 |
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygena | 2005 |
Concerns about COX-2 painkillers. They're easier on the stomach, potentially harder on your heart.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myo | 2002 |
The Vioxx debacle revisited.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Sulfonamid | 2005 |
Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance.
Topics: Aged; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; In Vitro Techniques; | 2005 |
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; | 2006 |
Unconvincing Pfizer and uncertain crucifixions.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Meta-Analysis as Topic; Myocardial Infa | 2006 |
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.
Topics: Age Factors; Aged; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Administration Sched | 2006 |
Celecoxib shown effective in preventing colon polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib | 2006 |
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; C | 2006 |
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
Topics: Aged; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2 Inhibito | 2007 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Stu | 2007 |
Risks and benefits of celecoxib to prevent colorectal adenomas.
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Huma | 2006 |
Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygen | 2007 |
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib | 2007 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 I | 2007 |
Balancing the risks and benefits of celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Dise | 2007 |
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Case-Control Studie | 2007 |
The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.
Topics: Animals; Celecoxib; Consciousness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dise | 2007 |
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Population Surveillan | 2007 |
Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Celecoxib; Competitive Medical Plans; Health Ma | 2007 |
Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?
Topics: Adult; Aged; Causality; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Databases, Fact | 2008 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh | 2008 |
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2000 |
Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2001 |
[New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
Topics: Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I | 2001 |
Is concern about cardiovascular events with the new coxib class of drugs justified?
Topics: Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Drug Evaluation; Humans; Lac | 2001 |
COX-2 inhibition and thrombotic tendency.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Sulfonamid | 2002 |